Advance in cytochrome P450 1 A2

Journal of Central South University (Medical Sciences)

Volumn 33, Issue 5, 2008, Pages 456-460

  Xiao, Peng ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP1A2; Drug metabolism; Genetic polymorphism

Indexed keywords

CARCINOGEN; CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A2;

DRUG DETOXIFICATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; METABOLISM; REVIEW;

CARCINOGENS; CYTOCHROME P-450 CYP1A2; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, GENETIC;

EID: 46049118467     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Nelson D R, Zeldin D C, Huffman S M, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants [J]. Pharmacogenetics, 2004,14(1):1-18.
2. ZHOU Hong-hao. Pharmacogenetics [M]. Beijing: People's Military Medical Press, 2003;53-54.
3. Ikeya K, Jaiswal A K, Owens R A, et al. Human CYP1 A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression [J]. Mol Endocrinol, 1989,3(9):1399-1408.
4. Quattrochi L C, Vu T, Tukey R H. The human CYP 1 A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH-receptor binding and promoter-specific induction [J]. J Biol Chem, 1994,269(9):6949-6954.
5. Chung I, Bresnick E. Regulation of the constitutive expression of the human CYP1 A2 gene; cis elements and their interactions with proteins [J]. Mol Pharmacol, 1995,47(4):677-685.
6. Pickwell G V, Shih H, Quattrochi L C. Interaction of upstream stimulatory factor proteins with an E-box located within the human CYP1 A2 5′-flanking gene contributes to basal transcriptional gene activation [J]. Biochem Pharmacol, 2003,65(7):1087-1096.
7. Chung I, Bresnick E. Identification of positive and negative regulatory elements of the human cytochrome P4501 A2 (CYP1 A2) gene [J]. Arch Biochem Biophys, 1997,338(2):220-226.
8. Soyama A, Saito Y, Hanioka N, et al. Single nucleotide polymorphisms and haplotypes of CYP1 A2 in a Japanese population [J]. Drag Metab Pharmacokinet, 2005,20(1):24-33.
9. Faber M S, Jetter A, Fuhr U. Assessment of CYP1 A2 activity in clinical practice why, how, and when ? [J]. Basic Clin Pharmacol Toxicol, 2005,97(3):125-134.
10. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5'-flanking region of human CYP l A2 gene: effect on the CYP1 A2 inducibility in humans [J]. J Biochem (Tokyo), 1999,125(4):803-808.
11. Han X M, Ou-Yang D S, Lu P X, et al. Plasma caffeine metabolite ratio (17 X/137X) in vivo associated with G-2964 A and C734 A polymorphisms of human CYP1 A2 [J]. Pharmacogenetics, 2001,11(5):429-435.
12. Hamdy S I, Hiratsuka M, Narahara K, et al. Genotyping of four genetic polymorphisms in the CYP1 A2 1 gene in the Egyptian population [J]. Br J Clin Pharmacol,2003,55(3):321-324.
13. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1 A 2 gene tested with caffeine [J]. Br J Clin Pharmacol, 1999,47(4):445-449.
14. Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1 A2 gene (CYP1 A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism [J]. Br J Clin Pharmacol, 2003,55(1):68-76.
15. Osawa Y, Osawa K K, Miyaishi A, et al. NAT2 and CYP1 A2 polymorphisms and lung cancer risk in relation to smoking status [J]. Asian Pac J Cancer Prev, 2007,8(1):103-108.
16. Aklillu E, Carrillo J A, Makonnen E, et al. Genetic polymorphism of CYP1 A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J]. Mol Pharmacol, 2003,64(3):659-669.
17. Chen X, Wang L, Zhi L, et al. The G-113 A polymorphism in CYP1 A2 affects the caffeine metabolic ratio in a Chinese population [J]. Clin Pharmacol Ther, 2005,78(3):249-259.
18. Rasmussen B B, Brix T H, Kyvik K O, et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1 A2 is determined by both genetic and environmental factors [J]. Pharmacogenetics, 2002,12(6):473-478.
19. TENG Jian-rong, ZHANG Shun-quan, CHEN Yue-ming, et al. Relationship between metabolism of clozapine in the body and polymorphisms of the locus cytochrome P450 1 A2-2964 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003,8(2):176-179.
20. Obase Y, Shimoda T, Kawano T, et al. Polymorphisms in the CYP1 A2 gene and theophylline metabolism in patients with asthma [J]. Clin Pharmacol Ther, 2003,73(5):468-474.
21. Johnson J A, Herring V L, Wolfe M S, et al. CYP1 A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences [J]. J Pharmacol Exp Ther, 2000,294(3):1099-1105.
22. Hengstler J G, Van der Burg B, Steinberg P, et al. Interspecies differences in cancer susceptibility and toxicity [J]. Drug Metab Rev, 1999,31(4):917-970.
23. Obach R S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression [J]. J Pharmacol Exp Ther, 2000,294(1):88-95.
24. von Moltke L L, Weemhoff J L, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba [J]. J Pharm Pharmacol, 2004,56(8):1039-1044.
25. Peng W X, Li H D, Zhou H H. Effect of daidzein on CYP1 A2 activity and pharmacokinetics of theophylline in healthy volunteers [J]. Eur J Clin Pharmacol, 2003,59 (3):237-241.